Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Exelon Patch 5 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Exelon Patch 5

Approved

STANDARD

Exelon Patch 5

LTS Lohmann Therapie-Systeme AG🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c235a9853e87960b
Company: LTS Lohmann Therapie-Systeme AG
Type: Standard

Approval Details

Approval Id: c235a9853e87960b
Drug Approval Philippines Name: Exelon Patch 5
Product Name: Exelon Patch 5
Registration Number: DRP-7420
Brand Name: Exelon Patch 5
Generic Name: Rivastigmine
Dosage Form: Transdermal Patch
Dosage Strength: 4.6mg/24 hours
Manufacturer: LTS Lohmann Therapie-Systeme AG
Importer: Novartis Healthcare Philippines, Inc.
Distributor: Novartis Healthcare Philippines, Inc.
Company Detail Path: /organization/lts-lohmann-therapie-systeme-ag
Issuance Date: 02 November 2023
Expiry Date: 07 October 2028
Pharmacologic Category: Anti-dementia
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c235a9853e87960b

Type

Standard

Back to Philippines FDA Approvals